MCAM (Melanoma Cell Adhesion Molecule), also known as CD146. is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. Initially identified in melanoma, it plays roles in cell adhesion, migration, signaling, and angiogenesis. MCAM is expressed in various cell types, including endothelial cells, smooth muscle cells, and activated T-cells, and is implicated in pathological processes such as cancer progression, inflammation, and vascular remodeling.
In oncology, MCAM overexpression correlates with aggressive tumor behavior, metastasis, and poor prognosis in cancers like melanoma, prostate, and breast cancer. Its involvement in epithelial-mesenchymal transition (EMT) and interactions with extracellular matrix components make it a therapeutic target. MCAM antibodies are tools for studying these mechanisms and have potential clinical applications.
Research-grade MCAM antibodies are used in immunohistochemistry, flow cytometry, and Western blotting to map expression patterns in tissues or cell lines. Therapeutically, anti-MCAM antibodies are explored for blocking tumor cell dissemination or angiogenesis. Some antibody-drug conjugates (ADCs) and bispecific antibodies targeting MCAM are under preclinical investigation.
Additionally, MCAM's role in autoimmune diseases (e.g., multiple sclerosis) and vascular disorders highlights its broader biomedical relevance. Despite challenges in specificity and off-target effects, MCAM remains a promising biomarker and intervention target, driving ongoing research into antibody-based diagnostics and therapies.
(Word count: 249)